Incoming health secretary unnerves pharma in-house counsel

Senior in-house sources in innovator and generic drug companies reveal to Managing IP that they’re concerned about Xavier Becerra’s pharma antitrust record
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article: